U.S. markets close in 6 hours 26 minutes

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2685+0.0035 (+1.32%)
As of 1:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2650
Open0.2586
BidN/A x N/A
AskN/A x N/A
Day's Range0.2580 - 0.2685
52 Week Range0.2570 - 1.5000
Volume25,425
Avg. Volume59,509
Market Cap14.51M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Newsfile

    Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

    Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta. Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of .

  • Newsfile

    Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

    Get a free ticket to the event here: https://microdose.buzz/nwdmtToronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharm

  • Newsfile

    Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emergency physician and addiction specialist, Dr. Dinesh Bayana as a medical advisor, providing expertise on the development of the Company's DMT clinical program as it relates to patient care in the context of addi